Via CD34 staining, we not only proved the association between MVD and the prognosis of pancreatic cancer, but also determined the relationship between β-catenin and angiogenesis, suggesting that the in vivo anti-cancer effect of a β-catenin pathway inhibitor could involve an antiangiogenic function targeting the tumor microenvironment. Here, CD34 is linked to familial pancreatic carcinoma.